Glenmark Pharmaceuticals Ltd.

is a mid-cap pharma company with strengths in dermatology, respiratory, and oncology, as well as a significant presence in generics globally. It leverages innovation, research-driven product launches, and exports to sustain revenue. Financial discipline and patent wins have improved margin trajectories. However, it faces generic pricing pressure, regulatory scrutiny, and litigation risks in key markets.